Study Groups

We are undertaking an individual patient data (IPD) meta-analysis to compare the safety and tolerability of artesunate-pyronaridine vs artesunate-amodiaquine, which is expected to inform a better understanding of the safety and tolerability of artesunate-pyronaridine relative to the related combination artesunate-amodiaquine that is currently more widely used in Africa.

This study group aims to determine the impact of malaria in the first trimester of pregnancy on the mother and infant through individual patient data meta-analysis (IPDMA).

The Plasmodium vivax fever study group aims to estimate parasitaemia thresholds for febrile patients who present for treatment and determine the pyrogenic density of vivax parasitaemia in recurrent infections.

The paediatric single low-dose (SLD) primaquine safety study group aims to describe and compare the safety of SLD primaquine for transmission blocking of Plasmodium falciparum in young children (under 5 years of age) with that in older children and adults.

The paediatric single low-dose (SLD) primaquine efficacy study group aims to assess and compare the efficacy of SLD primaquine for transmission blocking of Plasmodium falciparum in young children (under 5 years of age) with that in older children and adults

The Dihydroartemisinin-Piperaquine for Intermittent Preventive Treatment in Pregnancy Study Group aims to determine the safety and efficacy of intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine (DP) compared to IPTp with sulfadoxine-pyrimethamine (SP), for the prevention of malaria and adverse birth outcomes among pregnant women in sub-Saharan Africa.

This is an extension of the WWARN Haemoglobin-Haematocrit Relationship in Malaria Study Group and the Antimalarial–Antiretroviral Analyses Study Group. These groups aimed to consider the effect of HIV disease and co-administration of widely-used antiretroviral drugs (ARVs) on artemisinin-based combination therapies (ACTs).  

The overall aim of the IPTp and SP-resistance-associated mutations Study Group is to quantify how parasites with the sextuple mutant pfdhps and pfdhfr haplotype* modify the effect of IPTp on maternal and infant outcomes.

This is an extension of a planned dihydroartemisinin-piperaquine (DP) Safety Study Group, which aims to consider the effect of HIV disease and co-administration of widely-used antiretroviral (ARVs) on the safety of DP. Due to a lack of available DP studies, the individual patient data (IPD) meta-analysis will have greater public health value when these results were compared to other ACTs.

A meta-analysis of individual patient data (IPD) to determine the effect of antiretroviral (ARV) drug-drug interactions and HIV disease on artemether and lumefantrine pharmacokinetics (PK). The analysis aims to contribute evidence needed to inform recommendations on the use and optimal dosing of artemether-lumefantrine (AL) in HIV-infected patients.